Cited in:


This article has been cited by:

  1. 1
    Chuanpu Hu, Omoniyi Adedokun, Kaori Ito, Sangeeta Raje, Ming Lu, Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease, The Journal of Clinical Pharmacology, 2014, 54, 12
  2. 2
    Andrew T. Chow, Justin C. Earp, Manish Gupta, William Hanley, Chuanpu Hu, Diane D. Wang, Stefan Zajic, Min Zhu, Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions, The Journal of Clinical Pharmacology, 2014, 54, 5
  3. 3
    Matthew M. Riggs, Alexander Staab, Leo Seman, Thomas R. MacGregor, Timothy T. Bergsma, Marc R. Gastonguay, Sreeraj Macha, Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes, The Journal of Clinical Pharmacology, 2013, 53, 10
  4. 4
    Jane R. Kenny, Maggie M. Liu, Andrew T. Chow, Justin C. Earp, Raymond Evers, J. Greg Slatter, Diane D. Wang, Lei Zhang, Honghui Zhou, Therapeutic Protein Drug–Drug Interactions: Navigating the Knowledge Gaps–Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop, The AAPS Journal, 2013, 15, 4, 933


  5. 5
    Bernd Meibohm, Honghui Zhou, Characterizing the Impact of Renal Impairment on the Clinical Pharmacology of Biologics, The Journal of Clinical Pharmacology, 2012, 52, S1
  6. 6
    Min Zhu, Yu-Nien (Tom) Sun, Logistic Considerations in Study Design for Biologic Drug–Drug Interaction Assessments, Pharmaceutical Sciences Encyclopedia,
  7. 7
    Chuanpu Hu, Honghui Zhou, Statistical Considerations in Assessing Drug–Drug Interactions for Therapeutic Biologics, Pharmaceutical Sciences Encyclopedia,